Welcome to our dedicated page for Dermata Therapeutics SEC filings (Ticker: DRMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Spongilla microparticles, Phase 3 endpoints, and cash-runway disclosures: Dermata Therapeutics’ SEC filings pack dense biotechnology jargon into hundreds of pages. Finding where the 10-K discusses trial dropout rates or which Form 4 signals insider confidence can feel impossible.
Stock Titan solves this. Our AI reads every Dermata Therapeutics annual report 10-K simplified and each Dermata Therapeutics quarterly earnings report 10-Q filing, surfacing the R&D spend, patent expirations, and liquidity tables in plain English. Need fast alerts on Dermata Therapeutics Form 4 insider transactions real-time? We deliver them within seconds, flagging notable buys and sells. Curious about adverse-event disclosures? The platform links the exact line in the latest Dermata Therapeutics 8-K material events explained. It even answers natural questions like “Why did R&D jump this quarter?”—that’s understanding Dermata Therapeutics SEC documents with AI.
Whether you’re screening Dermata Therapeutics executive stock transactions Form 4, comparing segment costs across filings, or reviewing the Dermata Therapeutics proxy statement executive compensation, you’ll find it all here. Real-time updates from EDGAR ensure Dermata Therapeutics insider trading Form 4 transactions appear alongside our concise notes. Built-in charts provide Dermata Therapeutics earnings report filing analysis so you can track trial-driven revenue potential without wading through PDFs. Stop searching, start analyzing—every Dermata document, every insight, already distilled.
Dermata Therapeutics filed an 8-K announcing it has filed a prospectus supplement to increase the maximum aggregate offering amount of common stock issuable under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC by $1,792,315.
The company previously sold $1,662,142 of common stock under this agreement pursuant to a prior prospectus supplement. The filing also includes a legal opinion covering the additional $1,792,315 of shares tied to the Current Prospectus Supplement.
Dermata Therapeutics (DRMA) filed a prospectus supplement for its at-the-market program, permitting sales of up to $1,792,315 of common stock through H.C. Wainwright & Co. under its effective S-3, subject to General Instruction I.B.6 limitations.
This cap reflects a public float of approximately $5,376,945, calculated on 910,575 non‑affiliate shares at $5.905 as of September 16, 2025. The amount does not include approximately $1,662,142 previously sold under earlier supplements. Any additional sales capacity will be addressed in a subsequent supplement.
DRMA’s common stock trades on Nasdaq under “DRMA”; the last reported sale price was $2.95 on November 6, 2025. The company is an emerging growth company and smaller reporting company.
FAQ
What is the current stock price of Dermata Therapeutics (DRMA)?
What is the market cap of Dermata Therapeutics (DRMA)?
